Skip to main content

Table 5 Resource use by predictive biomarker testing status in Japan, Korea, Taiwan, and Brazil

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

 

Japan

(N = 175)

Korea

(N = 150)

Taiwan

(N = 217)

Brazil

(N = 175)

EGFR/ALK tested

Not tested

EGFR/ALK tested

Not tested

EGFR/ALK tested

Not tested

EGFR/ALK tested

Not tested

Pos

Neg/Unk

Pos

Neg/Unk

Pos

Neg/Unk

Pos

Neg/Unk

First-line therapy

N = 49

N = 81

N = 45

N = 53

N = 59

N = 38

N = 126

N = 59

N = 32

N = 13

N = 61

N = 101

No. inpatient staysa

44

129

69

89

82

80

90

83

27

5

17

20

 Hospital

44 (100)

129 (100)

69 (100)

89 (100)

82 (100)

80 (100)

90 (100)

83 (100)

27 (100)

5 (100)

17 (100)

20 (100)

No. hospitalizationsb

44

131

69

89

82

80

90

83

29

5

19

20

 Normal ward

44 (100)

129 (99)

69 (100)

89 (100)

82 (100)

80 (100)

90 (100)

83 (100)

27 (93)

4 (80)

17 (90)

20 (100)

 ICU

0

2 (2)

0

0

0

0

0

0

2 (7)

1 (20)

2 (11)

0

No. hospitalizations with LOSc

43

125

68

89

82

78

89

83

27

5

16

20

 Mean (SD) days

25.3 (16.9)

18.9 (15.4)

15.5 (12.8)

6.7 (7.4)

7.7 (11.1)

6.8 (9.9)

12.9 (14.7)

4.7 (3.3)

8.6 (8.6)

30.8 (24.2)

17.8 (25.7)

12.9 (14.8)

 Median (range)

21 (2–69)

13 (1–81)

13 (2–62)

3 (1–39)

3 (1–47)

3 (1–45)

7 (1–71)

3 (1–17)

5 (2–31)

22 (4–68)

6 (1–77)

6 (2–55)

Outpatient visits, nd

34

58

33

75

80

41

81

44

24

8

41

49

 Mean (SD) visits

17.5 (13.0)

14.9 (23.7)

16.5 (18.4)

11.8 (11.0)

14.2 (14.5)

11.3 (6.9)

16.3 (17.1)

8.0 (7.0)

17.0 (17.4)

8.3 (7.5)

9.5 (7.7)

5.1 (5.9)

 Median (range)

15 (1–51)

7 (1–124)

8 (1–62)

9 (1–51)

9 (1–58)

11 (1–27)

12 (1–109)

6 (1–27)

12 (2–76)

6 (2–22)

8 (1–35)

4 (1–36)

No. outpatient visits

595

863

546

882

1132

465

1321

352

407

66

389

251

Second-line therapy

N = 32

N = 46

N = 27

N = 37

N = 37

N = 22

N = 85

N = 44

N = 26

N = 8

N = 42

N = 41

No. inpatient staysa

26

27

24

29

18

32

120

28

13

1

11

10

 Hospital

26 (100)

27 (100)

24 (100)

29 (100)

18 (100)

31 (97)

120 (100)

28 (100)

13 (100)

1 (100)

11 (100)

10 (100)

 Hospice

0

0

0

0

0

1 (3)

0

0

0

0

0

0

No. hospitalizationsb

26

27

24

29

18

33

120

28

13

1

11

10

 Normal ward

26 (100)

27 (100)

24 (100)

29 (100)

17 (94)

31 (94)

120 (100)

28 (100)

13 (100)

1 (100)

11 (100)

10 (100)

 ICU

0

0

0

0

1 (6)

2 (6)

0

0

0

0

0

0

No. hospitalizations with LOSc

26

27

23

29

18

31

120

28

13

1

11

10

 Mean (SD) days

21.7 (15.0)

21.5 (16.2)

22.0 (16.4)

8.7 (11.5)

8.2 (7.1)

5.9 (5.4)

6.3 (7.4)

12.5 (15.7)

12.2 (10.5)

5.0 (n/a)

6.7 (5.3)

11.8 (8.8)

 Median (range)

17 (3–63)

17 (3–74)

15 (4–54)

4 (1–56)

8 (1–26)

2 (1–18)

3 (1–52)

6 (3–69)

9 (3–37)

5

6 (2–21)

9 (2–30)

Outpatient visits, nd

18

26

19

48

41

18

45

27

18

2

22

18

 Mean (SD) visits

6.8 (7.8)

7.9 (6.6)

16.1 (13.8)

14.8 (14.0)

8.6 (7.2)

9.6 (13.2)

11.7 (11.4)

19.9 (23.6)

17.8 (19.7)

3.0 (0)

5.7 (4.9)

2.9 (2.0)

 Median (range)

3 (1–24)

6 (1–26)

14 (2–49)

8 (1–49)

5 (1–21)

5 (1–45)

9 (1–55)

12 (1–92)

12 (1–68)

3 (3–3)

5 (1–18)

3 (1–6)

No. outpatient visits

122

205

305

710

351

172

525

537

320

6

126

53

  1. aTotal number of inpatient stays, defined as one or more nights in a hospital or hospice. There were no hospice stays in Japan, Korea, Taiwan, or Brazil in association with first-line therapy
  2. bTotal number of hospitalizations, not including hospice stays
  3. cTotal number of hospitalizations with non-missing data regarding length of stay (LOS)
  4. dNumber of patients who had ≥1 outpatient visits
  5. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, LOS length of stay, Neg/Unk negative/unknown, No. number of, OP outpatient, Pos positive